Search Bar & Filters
Found 1 Actively Recruiting clinical trials
Actively Recruiting
Researchers are evaluating INCB123667 compared to the investigators choice of chemotherapy in women with platinum-resistant ovarian cancer that shows cyclin E1 overexpression. This phase 3, randomized, open-label study aims to assess treatment options for this specific type of ovarian cancer, focusing on progression-free survival and overall survival over up to 2 years. Participants will receive either oral INCB123667 tablets at a dose defined by the study protocol or chemotherapy selected by the investigator according to protocol guidelines. The chemotherapy options are also given at protocol-defined doses. The study compares these two treatment approaches administered in parallel groups. During the trial, participants will be monitored for treatment responses and side effects, with evaluations including tumor measurements according to RECIST criteria and quality of life questionnaires at regular visits for up to 2 years. Safety assessments include tracking adverse events and dose modifications. The study will involve regular visits to assess progression-free survival, overall survival, and other clinical outcomes.